menu
    • menu
    [{"orgOrder":0,"company":"RepliCel","sponsor":"InnovaCell Biotechnologie","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Cultured, Autologous Hair Follicle Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"RepliCel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"RepliCel \/ InnovaCell Biotechnologie","highestDevelopmentStatusID":"6","companyTruncated":"RepliCel \/ InnovaCell Biotechnologie"},{"orgOrder":0,"company":"RepliCel","sponsor":"JensonR+ | PHARMALOG Institute | Syreon Corporation | Innovacell Biotechnologie | Datinf GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"RCS-01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"RepliCel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RepliCel \/ JensonR+ | PHARMALOG Institute | Syreon Corporation | Innovacell Biotechnologie | Datinf GmbH","highestDevelopmentStatusID":"6","companyTruncated":"RepliCel \/ JensonR+ | PHARMALOG Institute | Syreon Corporation | Innovacell Biotechnologie | Datinf GmbH"},{"orgOrder":0,"company":"RepliCel","sponsor":"Syreon Corporation | Innovacell Biotechnologie","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"RCT-01","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"RepliCel","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RepliCel \/ Syreon Corporation | Innovacell Biotechnologie","highestDevelopmentStatusID":"7","companyTruncated":"RepliCel \/ Syreon Corporation | Innovacell Biotechnologie"}]

    Find Clinical Drug Pipeline Developments & Deals by RepliCel

    Menu

    RepliCel

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RepliCel

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            RepliCel

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cultured, Autologous Hair Follicle Cell

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : InnovaCell Biotechnologie

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulat...

                            Details : RCS-01 is a patient-specific cell therapy in development to regenerate the extracellular tissue matrix under aging or sun-damaged skin characterized by fine wrinkles and loss collagen structure.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 09, 2021

                            Lead Product(s) : Cultured, Autologous Hair Follicle Cell

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : InnovaCell Biotechnologie

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RepliCel

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            RepliCel

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RCS-01

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : JensonR+ | PHARMALOG Institute | Syreon Corporation | Innovacell Biotechnologie | Datinf GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Intradermal Injections of RCS-01 in Male and Female Subjects

                            Details : RCS-01 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Skin Aging.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 18, 2015

                            Lead Product(s) : RCS-01

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : JensonR+ | PHARMALOG Institute | Syreon Corporation | Innovacell Biotechnologie | Datinf GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RepliCel

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            RepliCel

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RCT-01

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Syreon Corporation | Innovacell Biotechnologie

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis

                            Details : RCT-01 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Tendinopathy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 01, 2015

                            Lead Product(s) : RCT-01

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Syreon Corporation | Innovacell Biotechnologie

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth